Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Celgene and Acceleron initiate phase II ACE-011 study

Oct. 20, 2008

New agents for metabolic disorders disclosed in recent patents

Oct. 20, 2008

Bayer Schering Pharma completes decentralized approval procedure in EU for Qlaira

Oct. 17, 2008

Genzyme initiates enrollment in clinical trial of low-dose Fabrazyme in Fabry's disease

Oct. 17, 2008

MHRA grants approval to Insmed for phase I clinical study of INS-20

Oct. 17, 2008

Obesity candidate GRC-9332 described by Glenmark Pharmaceuticals

Oct. 17, 2008

BioMarin presents phase IIa results for 6R-BH4 in sickle cell disease

Oct. 16, 2008

URL submits NDA to the FDA for colchicine tablets in gout flares

Oct. 16, 2008

Lisofylline to be studied in phase II trial to improve islet cell transplant outcomes

Oct. 15, 2008

New agents for treating endocrine disorders divulged in recent patent literature

Oct. 15, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model
BioWorld Science
Camp4 Therapeutics Corp. has highlighted new preclinical data for CMP-002, the company’s lead investigational antisense oligonucleotide (ASO) therapeutic...